FORMA Therapeutics Collaborates with Arpeggio Biosciences to Explore Translational Utility of Drug Candidates

Arpeggio Biosciences will use its proprietary technology to identify immediate biological and genetic changes promoted by specific drug-target interactions

WATERTOWN, Mass. & BOULDER, Colo.--()--FORMA Therapeutics and Arpeggio Biosciences today announced a collaboration to utilize Arpeggio Biosciences’ proprietary technology to supplement FORMA’s analysis of the biological effects of its potential drug candidates. Arpeggio’s technology helps to identify the primary results of a drug’s impact on both biological and genetic activity. Unlike other techniques, this platform allows for systematic and rapid (within minutes of drug treatment) detection of response to treatment, providing information about a drug’s mechanism in complex cellular systems, resulting in better therapeutic insights. Data generated in this collaboration could enable FORMA to better understand the translational utility of its small molecule pipeline of therapeutics targeting cancer and other serious diseases.

Using Arpeggio’s powerful combination of nascent RNA-sequencing combined with machine learning, we will be able to differentiate responses due to primary modulation of the therapeutic target, from secondary and tertiary effects,” said Steven Tregay, Ph.D., President, CEO and Founder of FORMA Therapeutics. “This will provide us invaluable information as we make critical decisions on candidates having potential for utility across a multitude of therapeutics diseases.”

We are delighted to work with FORMA to expand their knowledge of potential drug candidates involved in gene control and protein homeostasis,” said Daniel Weaver Ph.D., CEO Arpeggio Biosciences. “Our platform is unique in its ability to understand proximal and critical biological impacts of a drug candidate, providing information that cannot be identified by any other means.”

FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, neurodegeneration, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates providing profound patient benefit.

FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with operations in Watertown, MA and Branford, CT.

About Arpeggio Biosciences
Arpeggio Biosciences leverages state-of-the art nascent transcript sequencing and combines it with machine learning to uncover novel insights into a compound’s biological mechanism of action. Its proprietary platform provides pharmaceutical and biotechnology companies with the ability to uncover systematically previously unobtainable information and intellectual property about their drug candidates.

Arpeggio Biosciences is based in Boulder, Colorado.


For FORMA Therapeutics
MacDougall Biomedical Communications
Kari Watson or Kara Mazey, +1 781-235-3060 or
For Arpeggio Biosciences
Dan Weaver, CEO

Recent Stories

RSS feed for FORMA Therapeutics

Release Summary

FORMA and Arpeggio Biosciences announced a collaboration to utilize Arpeggio's proprietary technology to supplement FORMA’s analysis of the biological effects of its potential drug candidates.

FORMA Therapeutics